www.leinco.com

Leinco Technologies, Inc.


excellence in early discovery research™

# Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) Purified

**Monoclonal Antibody** 

# **Product Information**

Product No.:	P383
Clone:	29F.1A12
RRID:	AB_2831656
Isotype:	Rat IgG2a к
Storage:	Sterile 2-8°C



Lane 1: 2 ug reduced recombinant mouse PD-1 (CD279)

Lane 2: 1 ug reduced recombinant mouse PD-1 (CD279)

Primary: anti-mouse PD-1 (CD279) antibody (29F.1A12) at 10 ug/ml (Prod. No. P383)

Secondary: HRP labeled goat anti-rat at 1:1000 dilution (Prod. No. R1215)

Predicted band size: ~40-60 kDa

# **Product Description**

#### **Specificity:**

Clone 29F.1A12 recognizes an epitope on mouse PD-1.

# Antigen Distribution:

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

# Background:

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. **Known Reactivity Species:** 

#### Mouse

#### Format:

Purified

# Immunogen:

PD-1 cDNA followed by PD-1-Ig fusion protein

# Formulation

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

# Storage and Stability

This purified antibody is stable when stored at 2-8°C. Do not freeze.

# Country of Origin

USA

# References

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed

2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

# **Product Datasheet**

www.leinco.com



excellence in early discovery research™

- 3.) Honjo, T. et al. (1992) EMBO J. 11:3887.
- 4.) Wurster S. et al. (2020) The Journal of Infectious Diseases 222(6):1989–994 Journal Link
- 5.) Lo, R. et al. (2021) Cancer Cell 39(10):1375-1387.e6 Journal Link